Cite
HARVARD Citation
Hollstein, T. et al. (2016). Treatment of therapy-refractory hypercholesterolemia with proprotein convertase subtilisin/kexin type 9 antibodies (PCSK9-I) in cardiovascular high risk patients – effectivity and safety in clinical routine. Atherosclerosis. pp. e48-. [Online].